Detalhe da pesquisa
1.
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.
Cell
; 184(9): 2348-2361.e6, 2021 04 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-33730597
2.
Antibody evasion by the P.1 strain of SARS-CoV-2.
Cell
; 184(11): 2939-2954.e9, 2021 05 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-33852911
3.
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum.
Cell
; 184(16): 4220-4236.e13, 2021 08 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34242578
4.
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera.
Cell
; 184(8): 2201-2211.e7, 2021 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33743891
5.
ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques.
Nature
; 586(7830): 578-582, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32731258
6.
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.
Clin Exp Immunol
; 211(3): 280-287, 2023 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36729167
7.
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
Lancet
; 398(10304): 981-990, 2021 09 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34480858
8.
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Lancet
; 396(10267): 1979-1993, 2021 12 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33220855
9.
Publisher Correction: ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques.
Nature
; 590(7844): E24, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33469217
10.
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Lancet
; 396(10249): 467-478, 2020 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32702298
11.
The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world.
Immunology
; 160(3): 223-232, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32460358
12.
Oral warfarin affects some aspects of systemic immunomodulation with topical dinitrochlorobenzene (DNCB) in rats.
Cutan Ocul Toxicol
; 37(1): 29-35, 2018 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-28486821
13.
Adenoviral vectored vaccination protects against Crimean-Congo Haemorrhagic Fever disease in a lethal challenge model.
EBioMedicine
; 90: 104523, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36933409
14.
Respiratory mucosal immune memory to SARS-CoV-2 after infection and vaccination.
Nat Commun
; 14(1): 6815, 2023 10 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37884506
15.
CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination.
JCI Insight
; 7(6)2022 03 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-35192547
16.
ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants.
Nat Commun
; 13(1): 4610, 2022 08 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35941149
17.
Efficacy of ChAdOx1 vaccines against SARS-CoV-2 Variants of Concern Beta, Delta and Omicron in the Syrian hamster model.
Res Sq
; 2022 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35194602
18.
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial.
EBioMedicine
; 85: 104298, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36229342
19.
Risk factors for Crimean-Congo Haemorrhagic Fever (CCHF) virus exposure in farming communities in Uganda.
J Infect
; 85(6): 693-701, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36108783
20.
An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females.
EBioMedicine
; 81: 104128, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35779491